Antonio Gil-Moreno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7710770/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel molecular profiles of endometrial cancer—new light through old windows. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 221-229.	1.2	188
2	Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer, 2006, 107, 1801-1811.	2.0	171
3	Molecular markers of endometrial carcinoma detected in uterine aspirates. International Journal of Cancer, 2011, 129, 2435-2444.	2.3	105
4	Intraoperative sentinel node identification in early stage cervical cancer using a combination of radiolabeled albumin injection and isosulfan blue dye injection. Gynecologic Oncology, 2004, 92, 845-850.	0.6	102
5	The EMT signaling pathways in endometrial carcinoma. Clinical and Translational Oncology, 2012, 14, 715-720.	1.2	95
6	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	7.9	88
7	Total laparoscopic radical hysterectomy (type II-III) with pelvic lymphadenectomy in early invasive cervical cancer. Journal of Minimally Invasive Cynecology, 2005, 12, 113-120.	0.3	81
8	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British Journal of Cancer, 2016, 115, 716-724.	2.9	76
9	Total laparoscopic radical hysterectomy with intraoperative sentinel node identification in patients with early invasive cervical cancer. Gynecologic Oncology, 2005, 96, 187-193.	0.6	75
10	A Differential Gene Expression Profile Reveals Overexpression of RUNX1/AML1 in Invasive Endometrioid Carcinoma. Cancer Research, 2004, 64, 8846-8853.	0.4	74
11	Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): Phase III Clinical Trial Comparing Surgical With Radiologic Staging in Patients With Stages IB2–IVA Cervical Cancer. Journal of Minimally Invasive Gynecology, 2014, 21, 3-8.	0.3	73
12	Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping of Exosome-Like Vesicles. PLoS ONE, 2016, 11, e0151339.	1.1	70
13	Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. American Journal of Obstetrics and Gynecology, 2021, 224, 65.e1-65.e11.	0.7	69
14	Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 1900.	1.0	67
15	Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols. Journal of Translational Medicine, 2016, 14, 180.	1.8	64
16	E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS ONE, 2017, 12, e0184439.	1.1	64
17	Human salivary microRNAs in Cancer. Journal of Cancer, 2018, 9, 638-649.	1.2	61
18	Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology, 2008, 110, S72-S76.	0.6	59

#	Article	IF	CITATIONS
19	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	2.3	59
20	ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer. Cancer Research, 2007, 67, 6753-6759.	0.4	57
21	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Annals of Oncology, 2008, 19, 327-331.	0.6	54
22	Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Molecular and Cellular Endocrinology, 2012, 358, 244-255.	1.6	54
23	Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis, 2009, 30, 1288-1297.	1.3	50
24	ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. International Journal of Cancer, 2012, 130, 1532-1543.	2.3	50
25	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clinical Cancer Research, 2017, 23, 6458-6467.	3.2	50
26	Comparison of robotic-assisted vs conventional laparoscopy for extraperitoneal paraaortic lymphadenectomy. Gynecologic Oncology, 2014, 132, 98-101.	0.6	49
27	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene, 2019, 38, 6035-6050.	2.6	49
28	A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis. Journal of Clinical Medicine, 2019, 8, 2029.	1.0	49
29	Analysis of survival after laparoscopic-assisted vaginal hysterectomy compared with the conventional abdominal approach for early-stage endometrial carcinoma: A review of the literature. Journal of Minimally Invasive Gynecology, 2006, 13, 26-35.	0.3	48
30	Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Human Pathology, 2009, 40, 1418-1426.	1.1	45
31	Change in clinical management of sentinel lymph node location in early stage cervical cancer. Gynecologic Oncology, 2011, 120, 353-357.	0.6	45
32	ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene, 2012, 31, 4778-4788.	2.6	45
33	An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009, 125, 257-263.	2.3	44
34	Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histology and Histopathology, 2006, 21, 197-204.	0.5	44
35	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer, 2018, 28, 514-523.	1.2	43
36	Sentinel Lymph Node Identification and Radical Hysterectomy with Lymphadenectomy in Early Stage Cervical Cancer: Laparoscopy Versus Laparotomy. Journal of Minimally Invasive Gynecology, 2008, 15, 531-537.	0.3	42

#	Article	IF	CITATIONS
37	Activated leukocyte cell adhesion molecule (<scp>ALCAM</scp>) is a marker of recurrence and promotes cell migration, invasion, and metastasis in earlyâ€stage endometrioid endometrial cancer. Journal of Pathology, 2017, 241, 475-487.	2.1	42
38	Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques. Journal of Minimally Invasive Gynecology, 2019, 26, 492-500.	0.3	42
39	PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery. European Journal of Cancer, 2020, 136, 149-158.	1.3	42
40	High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion. Molecular Cancer Therapeutics, 2011, 10, 1357-1366.	1.9	41
41	Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clinical and Experimental Metastasis, 2015, 32, 467-478.	1.7	40
42	Pretherapeutic Extraperitoneal Laparoscopic Staging of Bulky or Locally Advanced Cervical Cancer. Annals of Surgical Oncology, 2011, 18, 482-489.	0.7	39
43	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	2.3	39
44	Comparison of recurrence after vulvectomy and lymphadenectomy with and without sentinel node biopsy in early stage vulvar cancer. Gynecologic Oncology, 2006, 103, 865-870.	0.6	37
45	Molecular determinants of invasion in endometrial cancer. Clinical and Translational Oncology, 2007, 9, 272-277.	1.2	37
46	Location of aortic node metastases in locally advanced cervical cancer. Gynecologic Oncology, 2012, 125, 312-314.	0.6	37
47	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Modern Pathology, 2017, 30, 134-145.	2.9	36
48	Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Human Pathology, 2006, 37, 883-889.	1.1	35
49	Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. Journal of Pathology, 2005, 207, 422-429.	2.1	34
50	Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clinical and Translational Oncology, 2020, 22, 1272-1279.	1.2	34
51	Usefulness of sentinel lymph node detection in early stages of cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1210-1216.	3.3	32
52	Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Annals of Oncology, 2009, 20, 294-297.	0.6	32
53	Patient-Derived Xenograft Models for Endometrial Cancer Research. International Journal of Molecular Sciences, 2018, 19, 2431.	1.8	32
54	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. Scientific Reports, 2019, 9, 15057.	1.6	31

#	Article	IF	CITATIONS
55	Merkel Cell Carcinoma of the Vulva. Gynecologic Oncology, 1997, 64, 526-532.	0.6	30
56	ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. Carcinogenesis, 2014, 35, 2679-2686.	1.3	30
57	MicroRNAs as prognostic markers in ovarian cancer. Molecular and Cellular Endocrinology, 2014, 390, 73-84.	1.6	30
58	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. International Journal of Cancer, 2017, 140, 1551-1563.	2.3	30
59	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. Scientific Reports, 2017, 7, 8803.	1.6	30
60	EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. Journal of Translational Medicine, 2019, 17, 208.	1.8	30
61	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecologic Oncology, 2019, 153, 425-435.	0.6	30
62	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. Cancers, 2019, 11, 2000.	1.7	30
63	Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?. Gynecologic Oncology, 2005, 97, 292-295.	0.6	27
64	EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer. Cancers, 2019, 11, 839.	1.7	27
65	The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. Journal of Minimally Invasive Gynecology, 2020, 27, 462-463.	0.3	27
66	Laparoscopic Radical Hysterectomy with Pelvic Lymphadenectomy in Early Invasive Cervical Cancer. Journal of Minimally Invasive Gynecology, 2011, 18, 555-568.	0.3	26
67	Generation and characterization of orthotopic murine models for endometrial cancer. Clinical and Experimental Metastasis, 2012, 29, 217-227.	1.7	26
68	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	3.9	25
69	Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget, 2016, 7, 53102-53115.	0.8	24
70	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 585.	1.0	23
71	The up-regulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinomaa~†. Human Pathology, 2006, 37, 1050-1057.	1.1	22
72	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. Journal of Proteome Research, 2009, 8, 4676-4684.	1.8	22

#	Article	lF	CITATIONS
73	Analysis of Gene Expression Regulated by the <i>ETV5</i> Transcription Factor in OV90 Ovarian Cancer Cells Identifies <i>FOXM1</i> Overexpression in Ovarian Cancer. Molecular Cancer Research, 2012, 10, 914-924.	1.5	22
74	Nerve sparing technique in roboticâ€assisted radical hysterectomy: results. International Journal of Medical Robotics and Computer Assisted Surgery, 2013, 9, 339-344.	1.2	22
75	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	1.1	22
76	Importance of Enhanced Recovery After Surgery (ERAS) Protocol Compliance for Length of Stay in Ovarian Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 8979-8986.	0.7	22
77	Impact of extraperitoneal lymphadenectomy on treatment and survival in patients with locally advanced cervical cancer. Gynecologic Oncology, 2008, 110, S33-S35.	0.6	21
78	The surgical management of early-stage cervical cancer. Current Opinion in Obstetrics and Gynecology, 2013, 25, 312-319.	0.9	20
79	Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. European Journal of Surgical Oncology, 2015, 41, 635-640.	0.5	20
80	Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Review of Proteomics, 2018, 15, 81-99.	1.3	20
81	Prospective Randomized Trial Comparing Transperitoneal Versus Extraperitoneal Laparoscopic Aortic Lymphadenectomy for Surgical Staging of Endometrial and Ovarian Cancer: The STELLA Trial. Annals of Surgical Oncology, 2016, 23, 2966-2974.	0.7	19
82	Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecologic Oncology, 2021, 161, 787-794.	0.6	17
83	Diagnostic performance of transvaginal ultrasound and magnetic resonance imaging for preoperative evaluation of lowâ€grade endometrioid endometrial carcinoma: prospective comparative study. Ultrasound in Obstetrics and Gynecology, 2021, 58, 469-475.	0.9	17
84	Vulvar intraepithelial neoplasia. Aids, 2016, 30, 859-868.	1.0	16
85	Proteomic Characterization of Epithelial-Like Extracellular Vesicles in Advanced Endometrial Cancer. Journal of Proteome Research, 2019, 18, 1043-1053.	1.8	16
86	Technetium-99m-indocyanine green versus technetium-99m-methylene blue for sentinel lymph node biopsy in early-stage endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 311-317.	1.2	16
87	Apoptosis in epithelial ovarian tumours. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 130, 121-128.	0.5	15
88	Molecular diagnosis of endometrial cancer from uterine aspirates. International Journal of Cancer, 2013, 133, 2383-2391.	2.3	15
89	FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways. Frontiers in Oncology, 2019, 9, 1306.	1.3	15
90	Expression of DNA Damage Checkpoint Protein Hus1 in Epithelial Ovarian Tumors Correlates With Prognostic Markers. International Journal of Gynecological Pathology, 2008, 27, 24-32.	0.9	14

#	Article	IF	CITATIONS
91	Surgical approaches in women with endometrial cancer with a body mass index greater than 35 kg/m ² . Journal of Obstetrics and Gynaecology Research, 2019, 45, 195-202.	0.6	14
92	Risk Factors for Progression or Persistence of Squamous Intraepithelial Lesions Diagnosed During Pregnancy. Journal of Lower Genital Tract Disease, 2012, 16, 34-38.	0.9	13
93	A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. Gynecologic Oncology, 2020, 158, 614-621.	0.6	13
94	Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma. Clinical and Translational Oncology, 2021, 23, 1210-1219.	1.2	13
95	Total laparoscopic radical trachelectomy with intraoperative sentinel node identification for early cervical stump cancer. Journal of Minimally Invasive Gynecology, 2005, 12, 522-524.	0.3	12
96	Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus. Archives of Gynecology and Obstetrics, 2010, 282, 63-67.	0.8	12
97	Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecologic Oncology, 2019, 152, 270-277.	0.6	12
98	Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers, 2020, 12, 886.	1.7	12
99	Sentinel lymph node identification in a primary ductal carcinoma arising in the vulva. International Journal of Gynecological Cancer, 2007, 17, 471-477.	1.2	11
100	Extraperitoneal Laparoscopic Approach for Diagnosis and Treatment of Aortic Lymph Node Recurrence in Gynecologic Malignancy. Journal of Minimally Invasive Gynecology, 2010, 17, 570-575.	0.3	11
101	Vaginal Intraepithelial Neoplasia: Clinical Presentation, Management, and Outcomes in Relation to HIV Infection Status. Journal of Lower Genital Tract Disease, 2019, 23, 7-12.	0.9	11
102	Evaluation of the intraoperative human papillomavirus test as a marker of early cure at 12Åmonths after electrosurgical excision procedure in women with cervical highâ€grade squamous intraepithelial lesion: a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 99-105	1.1	11
103	Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction. Gynecologic Oncology, 2020, 158, 603-607.	0.6	11
104	ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer. Oncotarget, 2018, 9, 16648-16664.	0.8	11
105	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	2.9	10
106	External validation of de novo stress urinary incontinence prediction model after vaginal prolapse surgery. International Urogynecology Journal, 2019, 30, 1719-1723.	0.7	10
107	Prognostic Value and Therapeutic Implication of Laparoscopic Extraperitoneal Paraaortic Staging in Locally Advanced Cervical Cancer: A Spanish Multicenter Study. Annals of Surgical Oncology, 2020, 27, 2829-2839.	0.7	10
108	Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools. Oncology Reports, 2020, 44, 873-886.	1.2	10

#	Article	IF	CITATIONS
109	Aberrant expression of epithelial leucine-rich repeat containing G protein–coupled receptor 5–positive cells in the eutopic endometrium in endometriosis and implications in deep-infiltrating endometriosis. Fertility and Sterility, 2017, 108, 858-867.e2.	0.5	9
110	Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer. Gynecologic Oncology, 2021, 160, 83-90.	0.6	9
111	Robot-assisted Extraperitoneal Para-aortic Lymphadenectomy Is Associated with Fewer Surgical Complications: A Post Hoc Analysis of the STELLA-2 Randomized Trial. Journal of Minimally Invasive Gynecology, 2021, 28, 2004-2012.e1.	0.3	9
112	Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study. Gynecologic Oncology, 2021, 162, 32-37.	0.6	9
113	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene, 2022, 41, 1835-1850.	2.6	9
114	Nerve-Sparing Technique during Laparoscopic Radical Hysterectomy: Critical Steps. Journal of Minimally Invasive Gynecology, 2018, 25, 1144-1145.	0.3	8
115	In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer. Cancers, 2021, 13, 5052.	1.7	8
116	Malignant struma ovarii mimic clear cell carcinoma. Archives of Gynecology and Obstetrics, 2005, 271, 251-256.	0.8	7
117	Usefulness of extraperitoneal laparoscopic paraaortic lymphadenectomy for lymph node recurrence in gynecologic malignancy. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 723-730.	1.3	7
118	Anaphylaxis Associated with Blue Dye. New England Journal of Medicine, 2012, 367, 2026-2026.	13.9	7
119	Exenteración pélvica con resección rectal por neoplasias de distinto origen en dos centros de referencia. CirugÃa Española, 2018, 96, 138-148.	0.1	7
120	Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study. Gynecologic Oncology, 2020, 158, 287-293.	0.6	7
121	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers, 2021, 13, 2067.	1.7	7
122	Comparative study of polyvinylidene fluoride and polypropylene suburethral slings in the treatment of female stress urinary incontinence. Journal of Obstetrics and Gynaecology Research, 2016, 42, 291-296.	0.6	6
123	Risk Factors for Recurrence after Robot-Assisted Radical Hysterectomy for Early-Stage Cervical Cancer: A Multicenter Retrospective Study. Cancers, 2020, 12, 3387.	1.7	6
124	Tumor Size and Oncological Outcomes in Patients with Early Cervical Cancer Treated by Fertility Preservation Surgery: A Multicenter Retrospective Cohort Study. Cancers, 2022, 14, 2108.	1.7	6
125	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool. International Journal of Molecular Sciences, 2022, 23, 6266.	1.8	6
126	Extraperitoneal laparoscopic para-aortic lymphadenectomy for lymph node recurrence of fallopian tube carcinoma. International Journal of Gynecological Cancer, 2006, 16, 991-993.	1.2	5

#	Article	IF	CITATIONS
127	Clinical management of early-stage cervical cancer: The role of sentinel lymph node biopsy in tumors â‰ 2 â€ [−] cm. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 241, 30-34.	0.5	5
128	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology, 2019, 89, 90-98.	1.1	5
129	Long-term outcomes of retropubic tension-free vaginal tape for stress urinary incontinence after a transobturator tape failure: a retrospective study. International Urogynecology Journal, 2020, 31, 755-760.	0.7	5
130	Fertility preservation treatment of gynecological cancer patients in Spain: a national survey (GOFER) Tj ETQq0 0 (OrgBT ∣Ov 0.8	erlock 10 Tf
131	Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e78.	1.0	5
132	M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. Gynecologic Oncology, 2021, 161, 681-686.	0.6	5
133	Laparoscopic Debulking of Enlarged Pelvic Nodes during Surgical Para-aortic Staging in Locally Advanced Cervical Cancer: A Retrospective Comparative Cohort Study. Journal of Minimally Invasive Gynecology, 2022, 29, 103-113.	0.3	5
134	Nerve-sparing versus non-nerve-sparing radical hysterectomy: surgical and long-term oncological outcomes. Oncotarget, 2019, 10, 4598-4608.	0.8	5
135	Adjuvant therapy in early-stage cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis. Clinical and Translational Oncology, 2022, , 1.	1.2	5
136	Laparoscopic Isthmocele Repair with Hysteroscopic Assistance. Journal of Minimally Invasive Gynecology, 2018, 25, 576-577.	0.3	4
137	Role of office hysteroscopic morcellation and 3-dimensional transvaginal ultrasound in conservative management of retained placenta accreta. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 199-200.	0.5	4
138	Polypropylene and polyvinylidene fluoride transobturator slings for the treatment of female stress urinary incontinence: 1‥ear outcomes from a multicentre randomized trial. Neurourology and Urodynamics, 2021, 40, 475-482.	0.8	4
139	The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival. Journal of Gynecologic Oncology, 2021, 32, e4.	1.0	4
140	Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group. Gynecologic Oncology, 2021, 162, 407-412.	0.6	4
141	Potential strategies for prevention of tumor spillage in minimally invasive radical hysterectomy. Journal of Gynecologic Oncology, 2020, 31, e73.	1.0	4
142	Modified approach for extraperitoneal laparoscopic staging for locally advanced cervical cancer. Journal of Experimental and Clinical Cancer Research, 2007, 26, 451-8.	0.4	4
143	The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2022, 166, 8-17.	0.6	4
144	A giant superinfected uterine angioleiomyoma with distant septic metastases: an extremely rare presentation of a benign process and a systematic review of the literature. Archives of Gynecology and Obstetrics, 2019, 300, 841-847.	0.8	3

#	Article	IF	CITATIONS
145	Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients. Gynecologic and Obstetric Investigation, 2019, 84, 259-267.	0.7	3
146	Clinical Challenges in Managing Cervical Intraepithelial Neoplasia 2: A Report From a Cross-sectional Survey. Journal of Lower Genital Tract Disease, 2021, 25, 119-125.	0.9	3
147	The Impact of Surgical Practice on Oncological Outcomes in Robot-Assisted Radical Hysterectomy for Early-Stage Cervical Cancer, Spanish National Registry. Cancers, 2022, 14, 698.	1.7	3
148	Surgical Outcomes of Laparoscopic Pelvic Lymph Node Debulking during Staging Aortic Lymphadenectomy in Locally Advanced Cervical Cancer: A Multicenter Study. Cancers, 2022, 14, 1974.	1.7	3
149	To the Editor. Journal of Minimally Invasive Gynecology, 2006, 13, 488-489.	0.3	2
150	Comparison of Recurrence after Vulvectomy and Lymphadenectomy With and Without Sentinel Node Biopsy in Early Stage Vulvar Cancer. Obstetrical and Gynecological Survey, 2007, 62, 240-242.	0.2	2
151	Myeloid sarcoma as a simulator of advanced ovarian cancer: A case report. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 259-260.	0.5	2
152	Hysteroscopic myomectomy without anesthesia. Obstetrics and Gynecology Science, 2019, 62, 183.	0.6	2
153	Intraoperative Human Papillomavirus Test Predicts 24-Month High-Grade Squamous Intraepithelial Lesion Recurrence Saving Costs: A Prospective Cohort Study. Journal of Lower Genital Tract Disease, 2020, 24, 367-371.	0.9	2
154	Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas. Biomedicine and Pharmacotherapy, 2021, 140, 111744.	2.5	2
155	Longâ€ŧerm outcomes of transobturator suburethral tapes for female stress urinary incontinence. Neurourology and Urodynamics, 2022, 41, 391-398.	0.8	2
156	BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling. Scientific Reports, 2022, 12, 4445.	1.6	2
157	Mucocele of the Appendix. Journal of Minimally Invasive Gynecology, 2008, 15, 130-131.	0.3	1
158	Preaortic left primitive iliac vein. Journal of Vascular Surgery, 2012, 55, 1496.	0.6	1
159	Duplicated Renal Excretion System in an Extraperitoneal Laparoscopy for Para-Aortic Lymphadenectomy. Journal of Minimally Invasive Gynecology, 2014, 21, 972-973.	0.3	1
160	Breast cancer during pregnancy: matched study of diagnostic approach, tumor characteristics, and prognostic factors. Tumori, 2020, 106, 378-387.	0.6	1
161	ASO Visual Abstract: Importance of Enhanced Recovery After Surgery Protocol Compliance on Length of Stay in Ovarian Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 539-540.	0.7	1
162	Retro cervical tunneling to ensure correct placement for robotic-assisted transabdominal cerclage. Fertility and Sterility, 2021, 116, 1195-1196.	0.5	1

ANTONIO GIL-MORENO

#	Article	IF	CITATIONS
163	Fertility-Sparing Surgery versus Radical Hysterectomy in Early Cervical Cancer: A Propensity Score Matching Analysis and Noninferiority Study. Journal of Personalized Medicine, 2022, 12, 1081.	1.1	1
164	Carcinoma microinvasor de cérvix. El manejo de una neoplasia de buen pronóstico. Progresos En Obstetricia Y Ginecologia, 2008, 51, 209-214.	0.0	0
165	Micrometastases in para-aortic lymph nodes in advanced cervical cancer patients — Are a true predictor of recurrence at this level?. Gynecologic Oncology, 2011, 121, 639.	0.6	0
166	Reply to "Pretherapeutic Laparoscopic Paraaortic Staging in Advanced Cervical Cancer—Which Patients Should Be Considered?― Annals of Surgical Oncology, 2011, 18, 291-291.	0.7	0
167	Location of aortic node metastases in locally advanced cervical cancer. Gynecologic Oncology, 2012, 127, 677-678.	0.6	0
168	Laparoscopic Radical Hysterectomy with Pelvic Lymphadenectomy (Spanish School). , 2018, , 597-609.		0
169	When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions. Breast Care, 2021, 16, 630-636.	0.8	0
170	Intra-Abdominal Retained Products of Conception: A Rare Complication Postsurgical Abortion by Dilation and Evacuation. Journal of Gynecologic Surgery, 2021, 37, 263-266.	0.0	0
171	The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer Journal of Clinical Oncology, 2017, 35, e17070-e17070.	0.8	0
172	Robotic Radical Hysterectomy: Surgical Technique. , 2018, , 275-281.		0
173	Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812 Journal of Clinical Oncology, 2018, 36, e14556-e14556.	0.8	0

174 Prognostic factors in recurrent endometrial carcinoma. , 2002, 4, 429-436.

0